Adicet Bio (NASDAQ:ACET) Receives Buy Rating from Truist Financial

Truist Financial reiterated their buy rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $27.00 price objective on the stock. Several other research firms have also weighed in on ACET. StockNews.com started coverage on shares of Adicet Bio in a […]

Related Keywords

Carll Gordon ,Adicet Bio ,Carlyle Group Inc ,Securities Exchange Commission ,Blackrock Inc ,Adicet Bio Inc ,Jpmorgan Chase Co ,Adicet Bio Company Profile ,Truist Financial ,Free Report ,Bio Trading Down ,Get Free Report ,Director Carl ,Exchange Commission ,State Street Corp ,Street Corp ,Adicet Bio Daily ,Nasdaq Acet ,Facet ,Medical ,00444610 ,Reiterated Rating ,Truist Financial Co ,